Management Team

The management team includes Frank Otto Gombert and Philipp Knechtle. Frank Otto Gombert is an experienced researcher with strong background in pharma project management and drug development. He joined Selmod in 2019. Philipp Knechtle is an experienced microbiologist with strong experience in anti-infective discovery and clinical development. Start-up entrepreneur with the ambition to create a new biotech company. Additional experts will join our team accordingly during further progress of our drug candidates.

Frank Otto Gombert, Dr. rer. nat., CEO

Biochemist with a track record of 4 clinical candidates including an anti-bacterial drug. He previously was engaged at GPRS, Polyphor (phase 3 candidates Murapevadin and Balixafortide, phase 2 candidate POL6014), Novartis and Sandoz. He joined Selmod in 2019 as investor and CEO.
LinkedIn

Philipp Knechtle, Ph.D. CSO and co-founder

Philipp has a Ph.D. in Microbiology from the University of Basel and did his postdoc at the Institut Pasteur in Paris. Philipp's previous positions were antifungal compound development at Evolva and Polyphor. Philipp has joined Allecra Therapeutics SAS in 2017 and performed successfully the clinical development of EXBLIFEP® (cefepime-enmetazobactam) for Complicated Urinary Tract Infections.
LinkedIn


Board of Directors

The board of directors is formed by Dr. Philipp Knechtle (co-founder) and Dr. Markus Hofer (co-founder) and investors.

Markus Hofer, MBA, MSc, co-founder

Enterpreneurial Business building in Life Sciences. Experienced investor, manager and business leader. Focus on leadership team compositions and team building.
LinkedIn

Philipp Knechtle, Ph.D. CSO and co-founder

Philipp has a Ph.D. in Microbiology from the University of Basel and did his postdoc at the Institut Pasteur in Paris. Philipp's previous positions were antifungal compound development at Evolva and Polyphor. Philipp has joined Allecra Therapeutics SAS in 2017 and performed successfully the clinical development of EXBLIFEP® (cefepime-enmetazobactam) for Complicated Urinary Tract Infections.
LinkedIn


Advisory Board

The advisory board includes scientific from the fields of medicinal chemistry, pre-clinical to early clinical development, regulatory, clinical antifungal therapy, structural biology and financing experts.
Prof Dr. Roderich D. Süssmuth will join the advisory board after concluding the in-licensing of the Gyrase inhibitor from the TU Berlin. Additional experts in pharmacology and clinical development will join Selmod as advisors, while we are progressing with our drug development projects.

Sebastian Hiller, Prof. Dr., co-founder

Professor and scientific research group leader with expertise in membrane protein biochemistry, membrane protein biogenesis, and biophysical and biochemical methods for protein structure determination and characterization.
LinkedIn

Roderich D. Süssmuth, Prof. Dr.

Rudolf-Wiechert-Professor for Biological Chemistry at the Technical University of Berlin. His research group (~40 people) is active in molecular biology, biochemistry, analytical chemistry and organic synthesis and is dedicated to bioactive compounds, their biochemical assembly and chemical synthesis. He contributes his expertise in bioorganic and medicinal chemistry. Prof. Süssmuth is a member of the board of Pentracor GmbH (Henningsdorf, Germany) for the development of medical devices in the area of myocardial infarct, as well as a consultant to the CMO CORDEN Pharma.
biochemie.tu-berlin.de